Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AOI Pharma, Inc. |
---|---|
Information provided by: | AOI Pharma, Inc. |
ClinicalTrials.gov Identifier: | NCT00415064 |
This is a phase I study of perifosine in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma. The current protocol will enroll patients with relapsed or refractory multiple myeloma requiring second or third line therapy. Six patients each will be treated with at one of 4 dose levels in a phase 1 study. All patients will receive perifosine, lenalidomide and dexamethasone of each 28 day cycle. The doses of perifosine and lenalidomide will be varied in each group. The dose of dexamethasone will remain constant.
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: Perifosine Drug: Lenalidomide Drug: Dexamethasone |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety Study |
Official Title: | An Open-Label Phase I Study of the Safety of Perifosine in Combination With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma |
Estimated Enrollment: | 36 |
Study Start Date: | December 2006 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
This is a phase I study of perifosine in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma. All patients will receive lenalidomide daily for days 1 to 21 of each 28 day cycle. Perifosine will be given daily qhs with food. Dexamethasone will be given on days 1-4, 9-12 and 17-20 for 4 cycles. After 4 cycles dexamethasone will be given only on days 1-4. Four dose levels will be studied:
Six patients will be enrolled at each dose level until the maximum tolerated dose (MTD) is reached. Six additional patients will be treated at the MTD.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Major criteria:
Minor criteria:
Any of the following sets of criteria will confirm the diagnosis of multiple myeloma:
Exclusion Criteria:
United States, Michigan | |
AOI Pharmaceuticals Investigative Site | |
Ann Arbor, Michigan, United States, 48109 |
Study Chair: | Andrzej J Jakubowiak, MD, PhD | University of Michigan |
Responsible Party: | AOI Pharma, Inc. ( AOI Pharma, Inc. ) |
Study ID Numbers: | Perifosine 127 |
Study First Received: | December 20, 2006 |
Last Updated: | December 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00415064 |
Health Authority: | United States: Food and Drug Administration |
Multiple Myeloma Perifosine Lenalidomide Dexamethasone |
Dexamethasone Immunoproliferative Disorders Blood Protein Disorders Hematologic Diseases Blood Coagulation Disorders Lenalidomide Vascular Diseases Paraproteinemias |
Hemostatic Disorders Multiple Myeloma Hemorrhagic Disorders Multiple myeloma Lymphoproliferative Disorders Dexamethasone acetate Neoplasms, Plasma Cell |
Anti-Inflammatory Agents Neoplasms by Histologic Type Antineoplastic Agents, Hormonal Immune System Diseases Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Gastrointestinal Agents Antiemetics |
Hormones Glucocorticoids Pharmacologic Actions Neoplasms Autonomic Agents Therapeutic Uses Cardiovascular Diseases Peripheral Nervous System Agents Central Nervous System Agents |